Pulse Biosciences, Inc (PLSE): Price and Financial Metrics

Pulse Biosciences, Inc (PLSE): $7.20

0.16 (-2.17%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

PLSE Price/Volume Stats

Current price $7.20 52-week high $13.62
Prev. close $7.36 52-week low $3.78
Day low $6.81 Volume 118,185
Day high $7.59 Avg. volume 183,536
50-day MA $8.85 Dividend yield N/A
200-day MA $7.44 Market Cap 397.62M

PLSE Stock Price Chart Interactive Chart >


Pulse Biosciences, Inc (PLSE) Company Bio


Pulse Biosciences, a development stage medical device company, focuses on developing medical technologies based on sub-microsecond pulsed electric field technology to detect and treat skin cancer and enhance wound healing. The company was founded in 2014 and is based in Burlingame, California.


PLSE Latest News Stream


Event/Time News Detail
Loading, please wait...

PLSE Latest Social Stream


Loading social stream, please wait...

View Full PLSE Social Stream

Latest PLSE News From Around the Web

Below are the latest news stories about PULSE BIOSCIENCES INC that investors may wish to consider to help them evaluate PLSE as an investment opportunity.

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter

HAYWARD, Calif., December 20, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter. All patients were successfully discharged by treating physicians. Patients will continue to be monitored and

Yahoo | December 20, 2023

Executive Chairman of Pulse Biosciences Robert Duggan Buys More Stock

Pulse Biosciences, Inc. ( NASDAQ:PLSE ) shareholders (or potential shareholders) will be happy to see that the...

Yahoo | December 3, 2023

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode

HAYWARD, Calif., November 21, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA percutaneous electrode.

Yahoo | November 21, 2023

Chief Strategy Officer of Pulse Biosciences Picks Up 24% More Stock

Investors who take an interest in Pulse Biosciences, Inc. ( NASDAQ:PLSE ) should definitely note that the Chief...

Yahoo | November 18, 2023

Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

HAYWARD, Calif., November 15, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York.

Yahoo | November 15, 2023

Read More 'PLSE' Stories Here

PLSE Price Returns

1-mo -23.73%
3-mo -13.04%
6-mo 78.66%
1-year 20.81%
3-year -63.87%
5-year -53.79%
YTD -41.18%
2023 341.88%
2022 -81.30%
2021 -37.93%
2020 77.93%
2019 17.02%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!